{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF00788",
      "entity_text" : "RA",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ06447",
      "entity_text" : "Peficitinib",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Peficitinib, an orally bioavailable, once-daily JAK inhibitor that inhibits JAK1, JAK3, and TYK2 with greater specificity than JAK2, may modulate crucial cytokine receptor pathways in RA [XREF_BIBR, XREF_BIBR].",
  "reading_complete" : "2020-07-28T15:49:36Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:45:13Z",
  "trigger" : "modulate",
  "evidence" : [ "Peficitinib, an orally bioavailable, once-daily JAK inhibitor that inhibits JAK1, JAK3, and TYK2 with greater specificity than JAK2, may modulate crucial cytokine receptor pathways in RA" ],
  "pmc_id" : "6858430",
  "score" : 0
}